In patients who require a valve-in-valve (ViV) transcatheter procedure for a failed aortic bioprosthesis, the choice of ...

The findings underscore that pregnancy is “a crucial window of opportunity to optimize cardiovascular health,” researchers ...

Juan Granada speaks with Marc Dweck for insights on potential pharmacologic therapies that can impact the progression of ...

With a mix of causes and comorbidities, type 2 MI patients do better than type 1 early on, then face worse long-term outcomes ...

In top-line results, the phase III trial demonstrated a “highly clinically meaningful reduction” in 24-hour systolic BP.

Median follow-up duration for patients who survived to discharge after their index admission was 618 days. Over that span, 21 ...

MINNEAPOLIS, MN—Fewer than one-quarter of patients who have heart failure with reduced ejection (HFrEF) and no clinical ...

Evidence supporting inflammation’s ties to cardiovascular disease is “no longer exploratory but is compelling and clinically ...

As a complement to other biomarkers, the cytokine may aid in the decision to send patients home from the ED or admit them.

Patients had less clinical worsening when treated with this “wonder drug,” as one doctor called it, within a year of ...

Keeping these factors in check and adhering to the AHA’s Life’s Essential 8, is the best way to prevent CVD, say researchers.

The 12,000-patient trial of the PCSK9 inhibitor met its primary endpoints in high-risk individuals with no prior CV events.